Which has higher valuation & earnings, GMAB or ERAS?

Genmab A/S has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.90B 4.15 $963M $1.32 19.65 Erasca N/A N/A -$124.55M -$0.93 N/A

Is GMAB or ERAS more profitable?

Genmab A/S has a net margin of 21.05% compared to Erasca's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Erasca N/A -35.31% -29.49%

Does the media prefer GMAB or ERAS?

In the previous week, Erasca had 27 more articles in the media than Genmab A/S. MarketBeat recorded 30 mentions for Erasca and 3 mentions for Genmab A/S. Erasca's average media sentiment score of 0.01 beat Genmab A/S's score of 0.00 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 2 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ASND or ERAS?

In the previous week, Erasca had 20 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 30 mentions for Erasca and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Erasca's score of 0.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ERAS or BBIO?

In the previous week, Erasca had 17 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Erasca and 13 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.86 beat Erasca's score of 0.01 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AXSM or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Erasca's return on equity of -35.31% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -26.59% -267.16% -28.53% Erasca N/A -35.31% -29.49%

Does the media favor AXSM or ERAS?

In the previous week, Erasca had 21 more articles in the media than Axsome Therapeutics. MarketBeat recorded 30 mentions for Erasca and 9 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Erasca's score of 0.01 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ELAN or ERAS?

In the previous week, Erasca had 23 more articles in the media than Elanco Animal Health. MarketBeat recorded 30 mentions for Erasca and 7 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.88 beat Erasca's score of 0.01 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Erasca (ERAS) Competitors

$15.07 -0.01 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$15.02 -0.05 (-0.36%)

As of 07:43 PM Eastern

Compare

ERAS vs. GMAB, ASND, BBIO, AXSM, and ELAN

Should you buy Erasca stock or one of its competitors? MarketBeat compares Erasca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Erasca include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Erasca compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Genmab A/S currently has a consensus price target of $37.93, indicating a potential upside of 46.22%. Erasca has a consensus price target of $20.11, indicating a potential upside of 33.45%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Genmab A/S is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Genmab A/S has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Erasca has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.15	$963M	$1.32	19.65
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Genmab A/S has a net margin of 21.05% compared to Erasca's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Erasca	N/A	-35.31%	-29.49%

In the previous week, Erasca had 27 more articles in the media than Genmab A/S. MarketBeat recorded 30 mentions for Erasca and 3 mentions for Genmab A/S. Erasca's average media sentiment score of 0.01 beat Genmab A/S's score of 0.00 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats Erasca on 12 of the 16 factors compared between the two stocks.

How does Erasca compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Erasca has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Erasca has lower revenue, but higher earnings than Ascendis Pharma A/S. Erasca is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.27	-$258M	$8.67	27.52
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

In the previous week, Erasca had 20 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 30 mentions for Erasca and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Erasca's score of 0.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 57.87% compared to Erasca's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Erasca	N/A	-35.31%	-29.49%

Ascendis Pharma A/S presently has a consensus target price of $295.39, indicating a potential upside of 23.81%. Erasca has a consensus target price of $20.11, indicating a potential upside of 33.45%. Given Erasca's higher probable upside, analysts clearly believe Erasca is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

67.8% of Erasca shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to BridgeBio Pharma?

Erasca (NASDAQ:ERAS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Erasca had 17 more articles in the media than BridgeBio Pharma. MarketBeat recorded 30 mentions for Erasca and 13 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.86 beat Erasca's score of 0.01 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Erasca has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
BridgeBio Pharma	$502.08M	26.77	-$724.93M	-$3.74	N/A

67.8% of Erasca shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Erasca presently has a consensus price target of $20.11, suggesting a potential upside of 33.45%. BridgeBio Pharma has a consensus price target of $91.05, suggesting a potential upside of 32.66%. Given Erasca's higher probable upside, equities research analysts clearly believe Erasca is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

Erasca has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Erasca compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Erasca has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Erasca has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.50	-$183.17M	-$3.73	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Erasca had 21 more articles in the media than Axsome Therapeutics. MarketBeat recorded 30 mentions for Erasca and 9 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Erasca's score of 0.01 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Erasca has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Erasca's return on equity of -35.31% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Erasca	N/A	-35.31%	-29.49%

Axsome Therapeutics currently has a consensus target price of $258.95, suggesting a potential upside of 7.02%. Erasca has a consensus target price of $20.11, suggesting a potential upside of 33.45%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Axsome Therapeutics and Erasca tied by winning 8 of the 16 factors compared between the two stocks.

How does Erasca compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Erasca has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Erasca has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.46	-$232M	-$0.50	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Elanco Animal Health currently has a consensus price target of $28.55, suggesting a potential upside of 22.99%. Erasca has a consensus price target of $20.11, suggesting a potential upside of 33.45%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Erasca had 23 more articles in the media than Elanco Animal Health. MarketBeat recorded 30 mentions for Erasca and 7 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.88 beat Erasca's score of 0.01 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Erasca has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Erasca	N/A	-35.31%	-29.49%

Summary

Elanco Animal Health beats Erasca on 10 of the 16 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERAS vs. The Competition

Export

Metric	Erasca	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.69B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-16.20	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	14.35	8.29	10.79	6.50
Net Income	-$124.55M	$23.85M	$3.56B	$336.88M
7 Day Performance	12.63%	5.21%	1.67%	-0.22%
1 Month Performance	34.07%	2.19%	0.43%	0.77%
1 Year Performance	984.17%	60.99%	32.84%	31.57%

Erasca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERAS Erasca	2.4812 of 5 stars	$15.07 -0.1%	$20.11 +33.5%	+1,000.7%	$4.69B	N/A	N/A	120	Trending News Options Volume
GMAB Genmab A/S	4.0239 of 5 stars	$25.08 -0.6%	$37.93 +51.2%	+21.0%	$15.74B	$3.72B	19.00	3,029	Analyst Forecast Options Volume
ASND Ascendis Pharma A/S	4.9172 of 5 stars	$218.06 +1.1%	$295.39 +35.5%	+28.9%	$13.45B	$814.57M	25.15	1,189	Positive News Analyst Downgrade
BBIO BridgeBio Pharma	3.4915 of 5 stars	$66.80 -1.1%	$89.59 +34.1%	+65.2%	$13.23B	$502.08M	N/A	400
AXSM Axsome Therapeutics	2.5181 of 5 stars	$255.17 +0.6%	$256.79 +0.6%	+146.2%	$13.06B	$638.50M	N/A	380	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERAS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Erasca (ERAS) Competitors

ERAS vs. GMAB, ASND, BBIO, AXSM, and ELAN

How does Erasca compare to Genmab A/S?

Summary

How does Erasca compare to Ascendis Pharma A/S?

Summary

How does Erasca compare to BridgeBio Pharma?

Summary

How does Erasca compare to Axsome Therapeutics?

Summary

How does Erasca compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Erasca (ERAS) Competitors

ERAS vs. GMAB, ASND, BBIO, AXSM, and ELAN

How does Erasca compare to Genmab A/S?

Do analysts recommend GMAB or ERAS?

Which has more risk and volatility, GMAB or ERAS?

Do insiders and institutionals believe in GMAB or ERAS?

Which has higher valuation & earnings, GMAB or ERAS?

Is GMAB or ERAS more profitable?

Does the media prefer GMAB or ERAS?

Summary

How does Erasca compare to Ascendis Pharma A/S?

Which has more volatility and risk, ASND or ERAS?

Which has preferable earnings and valuation, ASND or ERAS?

Does the media prefer ASND or ERAS?

Is ASND or ERAS more profitable?

Do analysts recommend ASND or ERAS?

Do institutionals & insiders believe in ASND or ERAS?

Summary

How does Erasca compare to BridgeBio Pharma?

Does the media refer more to ERAS or BBIO?

Is ERAS or BBIO more profitable?

Which has stronger earnings and valuation, ERAS or BBIO?

Do insiders & institutionals have more ownership in ERAS or BBIO?

Do analysts recommend ERAS or BBIO?

Which has more volatility and risk, ERAS or BBIO?

Summary

How does Erasca compare to Axsome Therapeutics?

Which has more risk & volatility, AXSM or ERAS?

Which has preferable earnings & valuation, AXSM or ERAS?

Do institutionals and insiders hold more shares of AXSM or ERAS?

Does the media favor AXSM or ERAS?

Is AXSM or ERAS more profitable?

Do analysts recommend AXSM or ERAS?

Summary

How does Erasca compare to Elanco Animal Health?

Which has more risk & volatility, ELAN or ERAS?

Which has preferable valuation and earnings, ELAN or ERAS?

Do analysts rate ELAN or ERAS?

Does the media prefer ELAN or ERAS?

Do insiders and institutionals hold more shares of ELAN or ERAS?

Is ELAN or ERAS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools